Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.
VRCA · Verrica Pharmaceuticals Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Verrica Pharmaceuticals reported U.S. Wycanth product revenue of $5.7 million in the third quarter of 2026. One Phase III trial completed enrollment, the second exceeded 50% enrollment, and readouts are expected in the first quarter of 2027 and mid-2027.
Verrica Pharmaceuticals Inc. reported record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 57.9% year-over-year. COVE-2 enrollment is complete, with topline data expected in Q1 2027; COVE-3 enrollment exceeds 50%, with topline data expected in mid-2027.